Subcutaneous infliximab CT-P13 Remsima®SC

Pre-clinicalUNKNOWN

0 views this week 0 watching💤 Quiet

Interest: 22/100

Hype Score

Development Stage

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Inflammatory Bowel Diseases

Conditions

Inflammatory Bowel Diseases

Trial Timeline

Sep 6, 2021 → Sep 30, 2024

NCT ID

NCT04990258

About Subcutaneous infliximab CT-P13 Remsima®SC

Subcutaneous infliximab CT-P13 Remsima®SC is a pre-clinical stage product being developed by Celltrion for Inflammatory Bowel Diseases. The current trial status is unknown. This product is registered under clinical trial identifier NCT04990258. Target conditions include Inflammatory Bowel Diseases.

What happened to similar drugs?

8 of 20 similar drugs in Inflammatory Bowel Diseases were approved

Approved (8) Terminated (2) Active (12)

✅Infliximab + Infliximab + InfliximabCelltrionApproved

🔄CT-P13CelltrionPhase 3

🔄Infliximab subcutaneous + Immunosuppressive AgentsCelltrionPhase 3

✅fidaxomicinAstellas PharmaApproved

✅RisankizumabAbbVieApproved

✅Human Papillomavirus VaccineMerckApproved

✅BezlotoxumabMerckApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT04990258	Pre-clinical	UNKNOWN	Sep 6, 2021	Sep 30, 2024	Inflammatory Bowel Diseases

Competing Products

20 competing products in Inflammatory Bowel Diseases

See all competitors

Product	Company	Stage	Hype Score
Infliximab + Infliximab + Infliximab	Celltrion	Approved	50
CT-P13	Celltrion	Phase 3	36
Infliximab subcutaneous + Immunosuppressive Agents	Celltrion	Phase 3	47
fidaxomicin	Astellas Pharma	Approved	43
Eribulin + Adriamycin + Cyclophosphamide	Eisai	Phase 2	39
E6007 + E6007 + E6007 + E6007 + E6007 + E6007	Eisai	Phase 1	29
Placebo + MORF-057	Eli Lilly	Phase 2	42
Baricitinib + Baricitinib	Eli Lilly	Phase 2	35
LY3114062 SC + Placebo + LY3114062 IV	Eli Lilly	Phase 1	29
MORF-057 + Placebo	Eli Lilly	Phase 2	39
MORF-057	Eli Lilly	Phase 2	35
LY3009104	Eli Lilly	Phase 1	29
HRF2105 patch + Loxoprofen patch + placebo	Jiangsu Hengrui Medicine	Phase 2	31
Risankizumab	AbbVie	Approved	43
GC012F Injection infusion	AstraZeneca	Phase 1	36
AZD6793 + Placebo	AstraZeneca	Phase 1	29
Human Papillomavirus Vaccine	Merck	Approved	43
Pembrolizumab	Merck	Phase 2	31
Gardasil vaccine	Merck	Pre-clinical	26
Bezlotoxumab	Merck	Approved	35